Related Experiment Video

Updated: May 28, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Microglia-inhibiting activity of Parkinson's disease drug amantadine

Jong-Heon Kim1, Ho-Won Lee, Jaegyu Hwang

  • 1Department of Pharmacology, Kyungpook National University School of Medicine, Daegu, Korea.

Neurobiology of Aging
|November 1, 2011
PubMed

Insights

Amantadine, an antiviral and Parkinson's drug, may treat neuroinflammation by inhibiting microglial activation. This study shows amantadine reduces inflammatory mediators, suggesting a glia-targeted mechanism for Parkinson's disease (PD).

Area of Science:

  • Neuroscience
  • Pharmacology
  • Immunology

Background:

  • Amantadine is an established antiviral and antiparkinsonian medication.
  • Its precise mechanism of action in Parkinson's disease (PD) is not fully understood.
  • Neuroinflammation and microglial activation are implicated in neurodegenerative disease progression.

Purpose of the Study:

  • To investigate amantadine's potential inhibitory effects on microglial activation and neuroinflammation.
  • To explore the molecular pathways targeted by amantadine in microglia.

Main Methods:

  • In vitro studies using cultured microglial cells stimulated with bacterial lipopolysaccharide.
  • Assessment of inflammatory mediator expression and production.
  • In vitro microglia/neuron co-culture experiments.
  • In vivo studies using animal models of neuroinflammation and Parkinson's disease.

Main Results:

  • Amantadine demonstrated an inhibitory effect on the inflammatory activation of microglia.
  • The drug suppressed a key signaling pathway regulating microglial activation.
  • Amantadine reduced the expression and production of pro-inflammatory mediators.
  • Microglia-inhibiting activity was confirmed in co-culture and animal models.

Conclusions:

  • Amantadine may exert its therapeutic effects in neurodegenerative conditions by targeting microglia in the central nervous system.
  • The drug's ability to inhibit microglial inflammatory activation suggests a novel, glia-targeted mechanism of action.
  • These findings provide a molecular basis for amantadine's role in attenuating neuroinflammation relevant to Parkinson's disease.

More Related Videos

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...